Genmab — Maj 2021

[nohope]

Du er noget uambitøs trold.

[Sukkeralf]

E L - you need to support the Dutch biotechs

[Sukkeralf]

Do you have any insights/romours/guesses in why Paul Parren left Genmab?

[Sukkeralf]

rumours

[troldmanden]

Det ved jeg ikke om det er Nohope. Jeg mener i bund og grund kursen kom FOR højt op i forhold til casen tidligere. At der skulle/skal flere gode data og salg til for at understøtte den kurs

[troldmanden]

Og det er så hvad jeg håber på sker i 2. halvår

[troldmanden]

Jokeren er stadig voldgiften og dermed hexa
cd20

[Sukkeralf]

hexa CD38

[nohope]

Well, ikke vildt uenig.

[E_L]

no, I don't know @Sukkeralf, have been pondering that question myself... and even though I consider Genmab only a tiny little bit Dutch as well, I feel I support the Dutch biotechs already by more then a normal fair share
lol

[E_L]

old Halozyme press release on patent https://www.halozyme.com/investors/news-releases/news-release-details/2010/Halozyme-Announces-Issuance-of-US-Patent-for-rHuPH20-Enzyme-Platform/default.aspx

[E_L]

If royalty rates indeed start dropping by 50% from 2024, that makes a big difference in importance of the arbitration case (at least for me; i did not take this into account)

[troldmanden]

Naturligvis sukker

[Sukkeralf]

Regardig PP my thought was back then that maybe it was a bit hard to sit in that position with the almighty Jan as CEO and former head of research ! I could be hard to set your own footprints....

[E_L]

yea, that would be the logical thought, agree, specially if you see how PP keeps bringing up in various interviews etc how he was the inventor for many of the Genmab antibodies, it feels a bit as if he needs/ craves that feeling of recognition

[E_L]

Halo Q3 '19: The rHuPH20 patents expires in Europe in 2024 and in the US in 2027. In general, our royalty term continues until the latter of the last expiring rHuPH20 patent or 10 years post first commercial sale.

[E_L]

If rHuPH20 exclusivity expires during this 10 year term. There is a step down in the royalty rate of approximately 50% from expiry until the end of the 10-year term. And it's this design that allows us to project meaningful royalty revenues even beyond 2027. And there's also the potential to obtain additional co-formulation patents on certain novel at partner product, potentially extending the mid single-digit royalty term up to 20 years post patent filing date.

[E_L]

While each agreement is negotiated separately, and terms and conditions vary across the agreements. In general, the core formulation patents have the favorable effect on the duration of the royalty term and potentially delay the timing of the royalty step down.

[Bulder]

Can we conclude that this makes the first part of the arbitration even lesser important, since royalty expires sooner or later. And that the question of dara-patent is THE most important issue of the arbitration?

[E_L]

i am not sure, maybe there is a co-formulation patent as they write about and patent is even longer. a lot of annoying uncertainty...